Silencing and selective methylation of the normal topoisomerase I gene in camptothecin-resistant CEM/C2 human leukemia cells

Oncology Research

Volumn 8, Issue 7-8, 1996, Pages 295-301

  Fujimori, Akira ^a   Hoki, Yuko ^a   Popescu, Nicholas C ^b   Pommier, Yves ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

camptothecin; DNA methylation; drug resistance; gene regulation; topoisomerase 1

Indexed keywords

CAMPTOTHECIN; DNA TOPOISOMERASE; METHYLCYTOSINE; RESTRICTION ENDONUCLEASE; UNCLASSIFIED DRUG;

ARTICLE; CHROMOSOME 20; CYTOGENETICS; DNA DETERMINATION; GENE REARRANGEMENT; HUMAN; HUMAN CELL; LEUKEMIA CELL; METHYLATION; MULTIDRUG RESISTANCE; POINT MUTATION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SILENCER GENE;

EID: 0029825344     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. 1. Gupta, M.; Fujimori, A.; Pommier, Y. Eukaryotic DNA topoisomerases I. Biochim. Biophys. Acta. 1262:1-14; 1995.
2. 2. Chen, A. Y.; Liu, L. F. DNA topoisomerases: essential enzymes and lethal targets. Annu. Rev. Pharmacol. Toxicol. 94:194-218; 1994.
3. 3. Slichenmyer, W. J.; Rowinsky, E. K.; Donehower, R. C.; Kaufmann, S. H. The current status of camptothecin analogs as anticancer agents. J. Natl. Cancer Inst. 85: 271-287; 1993.
4. 4. Potmesil, M. Camptothecins: from bench research to hospital wards. Cancer Res. 54:1431-1439; 1994.
5. 5. Kapoor, R.; Slade, D.; Fujimori, A.; Pommier, Y.; Harker, W. Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin. Oncol. Res. 7:83-95; 1995.
6. 6. Andoh, T.; Ishii, K.; Suzuki, Y.; Ikegami, Y.; Kusunoki, Y.; Takemoto, Y.; Okada, K. Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc. Natl. Acad. Sci. USA 84:5565-5569; 1987.
7. 7. Kanzawa, F.; Sugimoto, Y.; Minato, K.; Kasahara, K.; Bungo, M.; Nakagawa, K.; Fujiwara, Y.; Liu, L. F.; Saijo, N. Establishment of a camptothecin analogue (CPT-11 )-resistant cell line of human nonsmall cell lung cancer: characterization and mechanism of resistance. Cancer Res. 50:5919-5924; 1990.
8. 8. Kubota, N.; Kanzawa, F.; Nishio, K.; Takeda, Y.; Ohmori, T.; Fujiwara, Y.; Terashima, Y.; Saijo, N. Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line. Biochem. Biophys. Res. Commun. 188:571-577; 1992.
9. 9. Tamura, H.-O.; Kohchi, C.; Yamada, R.; Ikeda, T.; Koiwai, O.; Patterson, E.; Keene, J. D.; Okada, K.; Kjeldsen, E.; Nishikawa, K.; Andoh, T. Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites. Nucl. Acids Res. 19:69-75; 1991.
10. 10. Tanizawa, A.; Pommier, Y. Topoisomerase I alteration in a camptothecin-resistant cell line derived from Chinese hamster DC3F cells in culture. Cancer Res. 52: 1848-1854; 1992.
11. 11. Fujimori, A.; Harker, W. G.; Kohlhagen, G.; Hoki, Y.; Pommier, Y. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. Cancer Res. 55:1339-1346; 1995.
12. 12. Chang, J.-Y.; Dethlefsen, L.; Barley, L.; Zhou, B.; Cheng, Y.-C. Characterization of camptothecin-resistant Chinese hamster lung cells. Biochem. Pharmacol. 43:2443-2452; 1992.
13. 13. Nagai, S.; Yamauchi, M.; Andoh, T.; Nishizawa, M.; Satta, T.; Kodera, Y. Establishment and characterization of human gastric and colonic xenograft lines resistant to CPT-11 (a new derivative of camptothecin). J. Surg. Oncol. 59:116-24; 1995.
14. 14. Pantazis, P.; Mendoza, J.; DeJesus, A.; Early, A.; Shaw, J.; Giovanella, B. Development of resistance to 9-nitrocamptothecin by human leukemia U-937 cells in vitro correlates with altered sensitivities to several anticancer drugs. Anti-Cancer Drugs 5:473-479; 1994.
15. 15. Rubin, E.; Pantazis, P.; Bharti, A.; Toppmeyer, D.; Giovanella, B.; Kufe, D. Identification of a mutant human topoisomerase I with intact catalytic activity and resistance to 9-nitro-camptothecin. J. Biol. Chem. 269:2433-2439; 1994.
16. 16.Benedetti, P.; Fiorani, P.; Capuani, L.; Wang, J. C. Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine. Cancer Res. 53:4343-4348; 1993.
17. 17. Pommier, Y.; Leteurtre, F.; Fesen, M.; Fujimori, A.; Bertrand, R.; Solary, E.; Kohlhagen, G.; Kohn, K. W. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest. 12: 530-542; 1994.
18. 18. Eng, W.; Francis, L.; Tan, K.; Mattern, M.; Hofmann, G.; Woessner, R.; Hertzberg, R.; Johnson, R. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content. Mol. Pharmacol. 38:471-480; 1990.
19. 19. Herman, J. G.; Merlo, A.; Mao, L.; Lapidus, R. G.; Issa, J.-P. J.; Davidson, N. E.; Sidransky, D.; Baylin, S. B. Inactivation of the CDKN2/p16/MTSl gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 55:4525-4530; 1995.
20. 20. Gonzalez-Zulueta, M.; Bender, C. M.; Yang, A. S.; Nguyen, T.-D.; Beart, R. W.; Van Tornout, J. M.; Jones, P. A. Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res. 55:4531-4535; 1995.
21. 21. Hsueh, C.-T.; Dolnick, B. J. Regulation of folate-binding protein gene expression by DNA methylation in methotrexate-resistant KB cells. Biochem. Pharmacol. 47:1019-1027; 1994.
22. 22. Pinkel, D.; Straume, T.; Gray, J. Cytogenetic analysis using quantitative, high-sensitivity, fluorescence hybridization. Proc. Natl. Acad. Sci. USA 83: 2934-2938; 1986.
23. 23. Zimonjic, D.; Popescu, N.; Matsui, T.; Ito, M.; Chihara, K. Localization of the human cholecystokinin-B/gastrin receptor gene to chromosome 11p15.4-15.5 by fluorescence in situ hybridization. Cytogenet. Cell Genet. 65:184-185; 1994.
24. 24. Popescu, N.; Zimonjic, D.; Hatch, C.; Bonner, W. Chromosomal mapping of the human histone H2A.Z gene to 4q24 by in situ fluorescence hybridization. Genomics 20:333-335; 1994.
25. 25. Miller, S. A.; Dykes, D. D.; Polesky, H. F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16:1215-; 1988.
26. 26. Ceder, H.; Solage, A.; Glaser, G.; Razin, A. Direct detection of methylated cytosine in DNA by use of the restriction enzyme MspI. Nucleic Acids Res. 6:2125-2132; 1979.
27. 27. Kunze, N.; Yang, G. C.; Jiang, Z. Y.; Hameister, H.; Adolph, S.; Wiedorn, K.-H.; Richter, A.; Knippers, R. Localization of the active type IDNA topoisomerase gene on human chromosome 20q11.2-13.1, and two pseudogenes on chromosomes 1q23-24 and 22q11.2-13.1. Hum. Genet. 84:6-10; 1989.
28. 28. Zimonjic, D. B.; Rezanka, L.; Di Paolo, J. A.; Popescu, N. C. Refined localization of the erbB-3 proto-oncogene by direct visualization of FISH signals on LUT-inverted and contrast-enhanced digital images of DAPI-banded chromosomes. Cancer Genet. Cytogenet. 80:100-102; 1995.
29. 29. Bjornsti, M.-A.; Benedetti, P.; Viglianti, G. A.; Wang, J. C. Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug camptothecin. Cancer Res. 49:6318-6323; 1989.
30. 30. Sugimoto, Y.; Tsukahara, S.; Oh-hara, T.; Isoe, T.; Tsuruo, T. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by monoclonal antibody. Cancer Res. 50:6925-6930; 1990.
31. 31.Wossener, R.; Eng, W.-K.; Hofmann, G.; Rieman, D.; McCabe, F.; Hertzberg, R. Camptothecin hyper-resistant P388 cells: drug-dependent reduction in topoisomerase I content. Oncol. Res. 4:481-488; 1993.
32. 32. Tan, K.; Mattern, M.; Eng, W.-K.; McCabe, F.; Johnson, R. Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. J. Natl. Cancer Inst. 81:1732-1735; 1989.
33. 33. Madelaine, I.; Prost, S.; Naudin, A.; Riou, G.; Lavelle, F.; Riou, J.-F. Sequential modifications of topoisomerase I activity in a camptothecin-resistant cell line established by progressive adaptation. Biochem. Pharmacol. 45:339-348; 1993.